177 related articles for article (PubMed ID: 11145893)
41. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Miller MD; Marthas ML; Margot NA; Dailey PJ; Canfield DR; Tarara RP; Cherrington JM; Aguirre NL; Bischofberger N; Pedersen NC
J Virol; 2000 Feb; 74(4):1767-74. PubMed ID: 10644348
[TBL] [Abstract][Full Text] [Related]
42. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
[TBL] [Abstract][Full Text] [Related]
43. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection.
Mori K; Yasutomi Y; Sawada S; Villinger F; Sugama K; Rosenwith B; Heeney JL; Uberla K; Yamazaki S; Ansari AA; Rübsamen-Waigmann H
J Virol; 2000 Jul; 74(13):5747-53. PubMed ID: 10846052
[TBL] [Abstract][Full Text] [Related]
44. Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Wick D; Self SG
Math Biosci; 2000 Jun; 165(2):115-34. PubMed ID: 10854614
[TBL] [Abstract][Full Text] [Related]
45. Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
Shen L; Shen Y; Huang D; Qiu L; Sehgal P; Du GZ; Miller MD; Letvin NL; Chen ZW
J Infect Dis; 2004 Oct; 190(8):1438-47. PubMed ID: 15378436
[TBL] [Abstract][Full Text] [Related]
46. The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy.
Clements JE; Li M; Gama L; Bullock B; Carruth LM; Mankowski JL; Zink MC
J Neurovirol; 2005 Apr; 11(2):180-9. PubMed ID: 16036796
[TBL] [Abstract][Full Text] [Related]
47. DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued.
Fuller DH; Rajakumar PA; Wu MS; McMahon CW; Shipley T; Fuller JT; Bazmi A; Trichel AM; Allen TM; Mothe B; Haynes JR; Watkins DI; Murphey-Corb M
Virology; 2006 Apr; 348(1):200-15. PubMed ID: 16439000
[TBL] [Abstract][Full Text] [Related]
48. Control of SIV rebound through structured treatment interruptions during early infection.
Lori F; Lewis MG; Xu J; Varga G; Zinn DE; Crabbs C; Wagner W; Greenhouse J; Silvera P; Yalley-Ogunro J; Tinelli C; Lisziewicz J
Science; 2000 Nov; 290(5496):1591-3. PubMed ID: 11090360
[TBL] [Abstract][Full Text] [Related]
49. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
García-Lerma JG; Cong ME; Mitchell J; Youngpairoj AS; Zheng Q; Masciotra S; Martin A; Kuklenyik Z; Holder A; Lipscomb J; Pau CP; Barr JR; Hanson DL; Otten R; Paxton L; Folks TM; Heneine W
Sci Transl Med; 2010 Jan; 2(14):14ra4. PubMed ID: 20371467
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy and therapeutic vaccines in HIV infection.
García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
[TBL] [Abstract][Full Text] [Related]
51. Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy.
Ching N; Yang OO; Deville JG; Nielsen-Saines K; Ank BJ; Sim MS; Bryson YJ
Pediatr Res; 2007 Jun; 61(6):692-7. PubMed ID: 17426646
[TBL] [Abstract][Full Text] [Related]
52. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
53. Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate.
Taber R; Rajakumar PA; Fuller DH; Trichel AM; Dowling P; Meleason D; Amedee A; Murphey-Corb M
Virology; 2006 Oct; 354(1):116-31. PubMed ID: 16884757
[TBL] [Abstract][Full Text] [Related]
54. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Van Rompay KK; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N
J Virol; 2004 May; 78(10):5324-37. PubMed ID: 15113912
[TBL] [Abstract][Full Text] [Related]
55. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Tsai CC; Follis KE; Sabo A; Beck TW; Grant RF; Bischofberger N; Benveniste RE; Black R
Science; 1995 Nov; 270(5239):1197-9. PubMed ID: 7502044
[TBL] [Abstract][Full Text] [Related]
56. Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection.
Thiebot H; Louache F; Vaslin B; de Revel T; Neildez O; Larghero J; Vainchenker W; Dormont D; Le Grand R
J Virol; 2001 Dec; 75(23):11594-602. PubMed ID: 11689641
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
Tsai CC; Emau P; Follis KE; Beck TW; Benveniste RE; Bischofberger N; Lifson JD; Morton WR
J Virol; 1998 May; 72(5):4265-73. PubMed ID: 9557716
[TBL] [Abstract][Full Text] [Related]
58. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques.
Zhang YJ; Putkonen P; Albert J; Ohman P; Biberfeld G; Fenyö EM
Virology; 1994 May; 200(2):583-9. PubMed ID: 7909969
[TBL] [Abstract][Full Text] [Related]
59. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Van Rompay KK; Singh RP; Brignolo LL; Lawson JR; Schmidt KA; Pahar B; Canfield DR; Tarara RP; Sodora DL; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):900-14. PubMed ID: 15220696
[TBL] [Abstract][Full Text] [Related]
60. Containing HIV after infection.
Walker BD; Rosenberg ES
Nat Med; 2000 Oct; 6(10):1094-5. PubMed ID: 11017132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
